Metastatic CDK12-Mutated Neuroendocrine Tumor of Lung Showed an Exceptional Response to Olaparib and Paclitaxel
- 1 November 2021
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 5 (5), 751-755
- https://doi.org/10.1200/po.20.00400
Abstract
No abstract availableThis publication has 21 references indexed in Scilit:
- CDK12: A Potent Target and Biomarker for Human Cancer TherapyCells, 2020
- The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung CancerClinical Cancer Research, 2018
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response–Targeted Therapies in Breast CancerMolecular Cancer Therapeutics, 2018
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and HeartJournal of Thoracic Oncology, 2015
- Comprehensive genomic profiles of small cell lung cancerNature, 2015
- Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 YearsClinical Lung Cancer, 2012
- The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genesGenes & Development, 2011
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandingsMolecular Oncology, 2011
- Neuroendocrine Tumors of the Lung: An UpdateArchives of Pathology & Laboratory Medicine, 2010
- Treatment of extensive-stage small cell lung carcinoma: current status and future prospectsEuropean Respiratory Journal, 2009